Lim Tae Joon, Lee Jee Han, Chang Sung-Goo, Lee Choong Hyun, Min Gyeong Eun, Yoo Koo Han, Jeon Seung Hyun
Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea.
Urol Int. 2010;85(4):475-8. doi: 10.1159/000321175. Epub 2010 Oct 26.
Adverse events associated with sunitinib, such as cardiac toxicities, renal damage, and hemostatic complications, are well known. The authors report 3 cases in which patients experienced severe life-threatening complications after commencing sunitinib treatment. One patient developed heart failure with dilation of the left ventricle and decrease in the ejection fraction after one cycle of sunitinib and required treatment with an angiotensin-converting enzyme inhibitor, loop diuretics, and dobutamine. Another patient developed coronary artery stenosis after one cycle of sunitinib and was managed through percutaneous coronary intervention. Although follow-on coronary angiography revealed normal findings after 6 further cycles of sunitinib, this patient eventually expired due to multi-organ failure. The third patient had chronic renal failure before sunitinib treatment and required hemodialysis due to acute-on-chronic renal failure after commencing sunitinib treatment.
与舒尼替尼相关的不良事件，如心脏毒性、肾损伤和止血并发症，是众所周知的。作者报告了3例患者在开始舒尼替尼治疗后出现严重的危及生命的并发症。1例患者在接受1个周期的舒尼替尼治疗后出现左心室扩张和射血分数降低的心力衰竭，需要使用血管紧张素转换酶抑制剂、袢利尿剂和多巴酚丁胺进行治疗。另1例患者在接受1个周期的舒尼替尼治疗后出现冠状动脉狭窄，并通过经皮冠状动脉介入治疗。尽管在后续6个周期的舒尼替尼治疗后冠状动脉造影显示结果正常，但该患者最终因多器官衰竭死亡。第3例患者在舒尼替尼治疗前患有慢性肾衰竭，开始舒尼替尼治疗后因慢性肾衰竭急性发作而需要进行血液透析。
